StockNews.com Upgrades Can-Fite BioPharma (NYSE:CANF) to Hold

StockNews.com upgraded shares of Can-Fite BioPharma (NYSE:CANF) from a sell rating to a hold rating in a report released on Tuesday morning.

Other equities analysts have also issued reports about the stock. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Can-Fite BioPharma in a research report on Tuesday. EF Hutton Acquisition Co. I upgraded Can-Fite BioPharma to a “strong-buy” rating in a report on Wednesday, July 17th.

Can-Fite BioPharma Price Performance

Shares of NYSE:CANF opened at $1.99 on Tuesday. The stock has a market capitalization of $7.04 million, a price-to-earnings ratio of -1.11 and a beta of 1.39. The business’s fifty day moving average price is $2.25 and its two-hundred day moving average price is $2.52. Can-Fite BioPharma has a fifty-two week low of $1.83 and a fifty-two week high of $4.69.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC lifted its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the quarter. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. 21.00% of the stock is currently owned by institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.